ADHXF Adherex Technologies Inc. featured news, full reports, and detailed charts
Adherex Technologies Inc. (ADHXF/ADHXF.PK) Wrap Up:
Adherex Technologies Inc., together with its subsidiaries, operates as a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. The company?s clinical product portfolio includes Eniluracil, a Phase I clinical trail product for the treatment of cancer; ADH-1, a Phase II clinical trail product for the treatment of melanoma; and Sodium thiosulfate, a Phase III clinical trail product to prevent hearing loss in children receiving cisplatin-based chemotherapy. Its preclinical product portfolio comprises backup peptides and small chemical molecule successors to ADH-1; peptides and small molecules targeted to inhibiting the metastatic spread of cancers; and peptides that combine angiolytic and antiangiogenic properties. The company has collaboration agreement with McGill University to develop, use, and market various cell adhesion technology and compounds. It also has license agreement with Oregon Health & Science University to intellectual property directed to thiol-based compounds, including STS and their use in oncology; and GlaxoSmithKline for the development of Eniluracil. The company was founded in 1996 and is based in Durham, North Carolina.Adherex Technologies Inc. (ADHXF:OTC)
|
Market Cap
6.4M
|
Total Revenue
--
|
|
|
EBITDA
8.7M
|
DILUTED EPS TTM
-0.07
|
|
|
P/E
--
|
P/S
--
|
|
|
Return On Asset
-85.82
|
Return On Equity
-210.73
|
|
| K = Thousands M = Millions B = Billions | ||
ADHXF Top Compensated Officers
Executives, Board Directors
Key developments for Adherex Technologies Inc. (ADHXF)
Adherex Technologies Inc. reported consolidated financial results for the third quarter and nine months ended September 30, 2009. The net loss for the third quarter was $35,000 or a loss of $0.00 per share compared to a net loss of $3,329,000 or a loss of $0.03 per share in the same period in 2008. Loss from operations was $340,000 against $3,299,000 last year. The net loss for the nine months was $3,219,000 or a loss of $0.02 per share compared to a net loss of $11,075,000 or a loss of $0.09 per share in the same period in 2008. Loss from operations was $3,253,000 against $11,246,000 last year.
Adherex Technologies Inc. reported cash form operations results for the third quarter and nine months ended September 30, 2009. For the quarter, net cash used in operating activities was $672,000 compared to $2,418,000 previous year period. For the nine months ended September 30, 2009, cash used in operating activities was $4,505,000 compared to $8,187,000 previous year period.
Adherex Technologies Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended.
ADHXF Competitors
| Company | Last | Change | |
| No competitor information is available for ADHXF. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | ADHXF | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 15.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ADHXF |
||
ADHXF transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||